...
首页> 外文期刊>BMC Gastroenterology >Extracorporeal liver support: trending epidemiology and mortality - a nationwide database analysis 2007–2015
【24h】

Extracorporeal liver support: trending epidemiology and mortality - a nationwide database analysis 2007–2015

机译:体外肝支持:流行病学和死亡率趋势-2007-2015年全国数据库分析

获取原文

摘要

Extracorporeal liver support therapies (ELS) are technical options (for bridge-to-recovery as well as bridge-to-transplant) in patients with acute liver dysfunction (e.g. acute liver failure (ALF), acute-on chronic liver failure (AoCLF) or decompensated chronic liver disease (decomp. CLD)) to reduce effects of failing hepatic detoxification functions. The present study investigates the real-life utilization of ELS (annual incidences), mortality rates as well as data regarding specific populations of liver transplantation in Germany. Data on patient cases receiving extracorporeal liver support therapy were identified in a nationwide data set from the Federal statistical Office of Germany from 1 January 2007 through 31 December 2015 and analyzed regarding in-hospital mortality, age- and sex-specific distribution and use of ELS in the context of liver transplantation. Mortality rates in patients with primary acute liver dysfunction and secondary acute liver dysfunction (in the context of cardiothoracic surgery) were evaluated. Annual incidences of ELS use remained stable between 0.39/100.000 in 2007 and 0.47/100.000 ELS in 2015. In-hospital mortality rate was 51.49% in the 2886 evaluated patient cases. Mortality was higher in men (56.04%) than in women (43.70) in the observed time period between 2007 and 2015. ELS utilization and case-related liver transplantation rates were low (12.47%). Since 2012, the annual numbers for ELS therapy in cardiosurgical patients exceeded the frequency of ELS utilization in cases of primary liver dysfunction (mortality rates: 68.39% versus 40.63%). ELS utilization remained stable between 2007 and 2015. Mortality rates are high in this patient population of acute liver dysfunction, especially in combination with case-related cardiothoracic surgery. ELS is rarely used in the setting of liver transplantation. In 2015, more than 50% of all ELS cases in Germany were performed in the context of cardiothoracic surgery.
机译:对于患有急性肝功能不全(例如急性肝衰竭(ALF),急性上慢性肝衰竭(AoCLF))的患者,体外肝支持疗法(ELS)是技术选择(用于桥接至恢复以及桥接至移植)或失代偿性慢性肝病(decomp。CLD)),以减轻肝脏排毒功能衰竭的影响。本研究调查了德国ELS的实际利用率(年发病率),死亡率以及有关特定人群肝移植的数据。从2007年1月1日至2015年12月31日在德国联邦统计局的全国数据集中确定了接受体外肝支持治疗的患者病例数据,并分析了院内死亡率,年龄和性别特异性分布以及ELS的使用在肝移植的背景下。评估了原发性急性肝功能不全和继发性急性肝功能不全(在心胸外科手术中)患者的死亡率。使用ELS的年发生率在2007年的0.39 / 100.000和2015年的0.47 / 100.000之间保持稳定。在2886例评估患者中,住院死亡率为51.49%。在2007年至2015年的观察时间段内,男性的死亡率较高(56.04%),女性的死亡率较高(43.70)。ELS利用率和病例相关肝移植率较低(12.47%)。自2012年以来,在原发性肝功能不全患者中,每年在心脏外科手术患者中进行ELS治疗的次数超过了ELS的使用频率(死亡率:68.39%对40.63%)。在2007年至2015年之间,ELS的使用率保持稳定。在此急性肝功能不全患者群体中,死亡率很高,尤其是与病例相关的心胸外科手术相结合。 ELS很少用于肝移植。 2015年,德国所有ELS病例中有50%以上是在心胸外科手术中进行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号